Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vext Science's Enterprise Value is €66.52 Mil.
Vext Science's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €2.94 Mil. Therefore, Vext Science's EV-to-FCF for today is 22.61.
The historical rank and industry rank for Vext Science's EV-to-FCF or its related term are showing as below:
FRA:VV5'
s EV-to-FCF Range Over the Past 10 Years
Min: -150.4 Med: -6.17 Max: 256.6
Current: 22.73
During the past 9 years, the highest EV-to-FCF of Vext Science was 256.60. The lowest was -150.40. And the median was -6.17.
FRA:VV5's EV-to-FCF is ranked better than 74.24% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs FRA:VV5: 22.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vext Science's PE Ratio (TTM) for today is calculated as:
Vext Science's share price for today is €0.155.
Vext Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vext Science EV-to-FCF Related Terms
Vext Science EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vext Science's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vext Science's EV-to-FCF falls into.
Vext Science's current Enterprise Value is €66.52 Mil.
Vext Science's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a EV-to-FCF of 22.61 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #144 out of 559 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is Vext Science's EV-to-FCF too high?
Vext Science's current EV-to-FCF is 22.61. The Drug Manufacturers industry median EV-to-FCF is 20.58. Vext Science's value of 22.61 is 9.9% above this industry median. Based on the distribution chart, Vext Science ranks #144 out of 559 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vext Science has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #144 out of 559 companies for EV-to-FCF. This puts Vext Science in the upper half of its industry. The industry median EV-to-FCF is 20.58. Vext Science's value of 22.61 is 9.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current EV-to-FCF of 22.61 is 9.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current EV-to-FCF is 22.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current EV-to-FCF of 22.61. The stock's GF Value™ is €0.16, compared to a current price of €0.16 — trading 3.1% below its estimated fair value. The current EV-to-FCF is 22.61 and 9.9% above the Drug Manufacturers industry median of 20.58. Vext Science's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current EV-to-FCF is 22.61 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.16 is trading 3.1% below its estimated GF Value™ of €0.16.
Key valuation signals for FRA:VV5:
EV-to-FCF: 22.61
GF Value™: €0.16 vs. price of €0.16 (3.1% below fair value)
Industry Position: 9.9% above the Drug Manufacturers median (#144 of 559)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
41GF Score
Get the complete analysis for FRA:VV5
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
